Limits...
Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis.

Lu J, Lu J, Chen W, Huo Y, Huang X, Hou J, Chinese Medical Doctor Association Hematology Bran - Blood Cancer J (2014)

Bottom Line: The overall survival (OS) benefit was more prominent in IgG than in IgD when patients received bortezomib; however, they showed no significant difference when they received older therapies such as melphalan combined with prednisone or vincristine combined with adriamycin and dexamethasone.Conventional cytogenetics revealed that 13.3% were hypodiploid and those cases had the worst survival, but hyperdiploid cases (9.3%) did not show any survival benefit compared with those with a normal karyotype (77.4%).MM in mainland China presents with different features, with patients being of younger age and having higher risk and more survival benefit in IgG patients receiving bortezomib.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, People's Hospital, Beijing University, Beijing, China.

ABSTRACT
The aim of this study was to understand the clinical features and treatment outcome of Chinese patients with multiple myeloma (MM). This retrospective study enrolled 940 newly diagnosed inpatients (median age, 59 years; immunoglobulin (Ig)D isotype, 6.5%) with complete follow-up data at three centers. In all, 85.8% of patients were of Durie-Salmon stage III and 48.3% were of International Staging System (ISS) stage III at diagnosis. Also, 9.6% of patients had extramedullary plasmacytoma. Compared with IgG, IgD-type patients were diagnosed at a younger age, and more patients were of ISS stage III, with hypercalcemia, elevated levels of lactate dehydrogenase, hyperuricemia, renal dysfunction and 1q21 amplification (P=0.03). The overall survival (OS) benefit was more prominent in IgG than in IgD when patients received bortezomib; however, they showed no significant difference when they received older therapies such as melphalan combined with prednisone or vincristine combined with adriamycin and dexamethasone. Fluorescence in situ hybridization (FISH) results showed that 17.6% had 17p13 deletion. Conventional cytogenetics revealed that 13.3% were hypodiploid and those cases had the worst survival, but hyperdiploid cases (9.3%) did not show any survival benefit compared with those with a normal karyotype (77.4%). Median OS and progression-free survival for all patients were 54 and 26 months, respectively. Significant factors for survival by multivariate analysis were gender, ISS stage, number of FISH abnormalities and extramedullary disease. MM in mainland China presents with different features, with patients being of younger age and having higher risk and more survival benefit in IgG patients receiving bortezomib.

Show MeSH

Related in: MedlinePlus

OS and PFS in IgG and IgD patients who received bortezomib.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4219472&req=5

fig1: OS and PFS in IgG and IgD patients who received bortezomib.

Mentions: For patients who received bortezomib treatment, median OS was not reached. The mean OS for IgG and IgD was 50 and 47 months, respectively (P=0.11; Figure 1, when the Breslow method was used to analyze the survival difference, P=0.03), and the median PFS for both was 36 months (P=0.79). When the patients received MP (melphalan combined with prednisone) or VAD (vincristine combined with adriamycin and dexamethasone) treatment regimens, the median OS for IgG and IgD was 48 and 40 months, respectively (P=0.59; Figure 2). The PFS was 23 and 25 months, respectively (P=0.59; Figure 2). Whether or not IgD patients received bortezomib treatment, they showed no significant difference in OS (P=0.55) and PFS (P=0.30). IgG patients who received bortezomib treatment achieved survival benefit, not only for PFS but also for OS (P<0.001 and P<0.001, respectively; Figure 3).


Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis.

Lu J, Lu J, Chen W, Huo Y, Huang X, Hou J, Chinese Medical Doctor Association Hematology Bran - Blood Cancer J (2014)

OS and PFS in IgG and IgD patients who received bortezomib.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4219472&req=5

fig1: OS and PFS in IgG and IgD patients who received bortezomib.
Mentions: For patients who received bortezomib treatment, median OS was not reached. The mean OS for IgG and IgD was 50 and 47 months, respectively (P=0.11; Figure 1, when the Breslow method was used to analyze the survival difference, P=0.03), and the median PFS for both was 36 months (P=0.79). When the patients received MP (melphalan combined with prednisone) or VAD (vincristine combined with adriamycin and dexamethasone) treatment regimens, the median OS for IgG and IgD was 48 and 40 months, respectively (P=0.59; Figure 2). The PFS was 23 and 25 months, respectively (P=0.59; Figure 2). Whether or not IgD patients received bortezomib treatment, they showed no significant difference in OS (P=0.55) and PFS (P=0.30). IgG patients who received bortezomib treatment achieved survival benefit, not only for PFS but also for OS (P<0.001 and P<0.001, respectively; Figure 3).

Bottom Line: The overall survival (OS) benefit was more prominent in IgG than in IgD when patients received bortezomib; however, they showed no significant difference when they received older therapies such as melphalan combined with prednisone or vincristine combined with adriamycin and dexamethasone.Conventional cytogenetics revealed that 13.3% were hypodiploid and those cases had the worst survival, but hyperdiploid cases (9.3%) did not show any survival benefit compared with those with a normal karyotype (77.4%).MM in mainland China presents with different features, with patients being of younger age and having higher risk and more survival benefit in IgG patients receiving bortezomib.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, People's Hospital, Beijing University, Beijing, China.

ABSTRACT
The aim of this study was to understand the clinical features and treatment outcome of Chinese patients with multiple myeloma (MM). This retrospective study enrolled 940 newly diagnosed inpatients (median age, 59 years; immunoglobulin (Ig)D isotype, 6.5%) with complete follow-up data at three centers. In all, 85.8% of patients were of Durie-Salmon stage III and 48.3% were of International Staging System (ISS) stage III at diagnosis. Also, 9.6% of patients had extramedullary plasmacytoma. Compared with IgG, IgD-type patients were diagnosed at a younger age, and more patients were of ISS stage III, with hypercalcemia, elevated levels of lactate dehydrogenase, hyperuricemia, renal dysfunction and 1q21 amplification (P=0.03). The overall survival (OS) benefit was more prominent in IgG than in IgD when patients received bortezomib; however, they showed no significant difference when they received older therapies such as melphalan combined with prednisone or vincristine combined with adriamycin and dexamethasone. Fluorescence in situ hybridization (FISH) results showed that 17.6% had 17p13 deletion. Conventional cytogenetics revealed that 13.3% were hypodiploid and those cases had the worst survival, but hyperdiploid cases (9.3%) did not show any survival benefit compared with those with a normal karyotype (77.4%). Median OS and progression-free survival for all patients were 54 and 26 months, respectively. Significant factors for survival by multivariate analysis were gender, ISS stage, number of FISH abnormalities and extramedullary disease. MM in mainland China presents with different features, with patients being of younger age and having higher risk and more survival benefit in IgG patients receiving bortezomib.

Show MeSH
Related in: MedlinePlus